How would use of adjuvant atezolizumab for PDL1+ NSCLC potentially impact your treatment choice at recurrence?

Certainly pattern of relapse is important, and those with local or locoregional recurrences could be treated with definitive intent SBRT, surgery, or concurrent chemotherapy and radiation for mediastinal recurrence.

For those with recurrent not amenable to local therapy, this is a challenging questi...

A disease that recurs within a short period of time from completion of systemic therapy is typically considered refractory to it. My usual cut off for considering re-challenge is 6 months, which is amply utilized in clinical trials as eligibility criteria for patients presenting with metastatic recu...